联环药业（600513）公告，公司于2025年7月24日召开第九届董事会第十二次临时会议，审议通过了 《关于公司拟发行科技创新债券的议案》。公司计划向中国银行间市场交易商协会申请注册发行最高不 超过人民币5亿元(含5亿元)科技创新债券。债券将采用公开发行方式，期限不超过3年，具体期限由公 司与主承销商根据市场情况决定。募集资金将用于新药研发等核心业务活动，以提升研发效率并增强公 司应对药物研发挑战的能力。本次发行尚需公司股东会审议批准及中国银行间市场交易商协会的批准。 ...

注册分类：化学药品 证券代码：600513 证券简称：联环药业 公告编号：2025—048 江苏联环药业股份有限公司 关于公司药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的关于非洛地平片（联环尔定）（以 下简称"本品"）《药品补充申请批准通知书》，批准公司本品通过仿制药质量 和疗效一致性评价（以下简称"一致性评价"）。现将相关情况公告如下： 一、药品基本信息 药品名称：非洛地平片 商品名称：联环尔定 剂型：片剂 规格：2.5mg 原药品批准文号：国药准字 H10970111 药品注册标准编号：YBH17602025 受理号：CYHB2450389 通知书编号：2025B03261 审批结论：经审查，本品通过仿制药质量和疗效一致性评价。 二、药品的其他情况 非洛地平片是一种二氢吡啶类钙通道阻滞剂，用于轻、中度原发性高血压的 治疗。同时，公司目前还拥有的高血压治疗药物为非洛地平缓释胶囊、奥 ...

近日该股表现 联环药业再度涨停，11个交易日内录得7个涨停，累计涨幅为70.49%，累计换手率为198.76%。截至 11:29，该股今日成交量6303.19万股，成交金额11.14亿元，换手率22.08%。最新A股总市值达52.61亿 元。 龙虎榜数据显示，该股因连续三个交易日内，涨幅偏离值累计达20%、日跌幅偏离值达7%、日换手率 达20%上榜龙虎榜5次，买卖居前营业部中，机构净买入1.14亿元，营业部席位合计净卖出4590.93万 元。 4月30日公司发布的一季报数据显示，一季度公司共实现营业总收入6.28亿元，同比增长18.78%，实现 净利润0.23亿元，同比下降29.15%。（数据宝） | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.07.18 | 0.66 | 23.69 | 277.99 | | 2025.07.17 | 2.02 | 27.60 | -9191.42 | | 2025.07.16 | 9.98 | 18.86 | 9522.45 | | 2025.07.15 | -10.01 ...

Group 1: Super Hydropower Project - The Chinese government announced the commencement of a super hydropower project with an investment of 1.2 trillion yuan on July 19 [7][21][13] - Multiple stocks related to hydropower and construction saw significant increases, with companies like Zhongbo Design and China Power Construction rising by 20.03% and 10.04% respectively [1][2] - The project is expected to boost the construction and materials sectors, with various companies in concrete and cement also experiencing stock price increases [3][4][19] Group 2: Robotics and Technology - Yushu Technology has begun its IPO guidance with CITIC Securities as the advisory firm, leading to stock price increases for companies like Shangwei New Materials, which rose by 19.99% [5] - Several companies involved in robotics and technology, such as Zhuochen Technology and Wolong Electric Drive, also saw stock price increases due to their association with Yushu Technology [6][11] Group 3: Infrastructure and Construction - Stocks related to infrastructure and construction, including Changjian Group and China Energy Construction, experienced price increases following the announcement of the super hydropower project [7][8] - The construction materials sector, particularly cement and concrete companies, showed strong performance with multiple stocks hitting their daily price limits [3][4] Group 4: Military and Defense - The military and defense sector is expected to see a revaluation of companies due to ongoing geopolitical conflicts, with stocks like Beihua Co. and Construction Industry rising in response [28][29] - The focus on military exports and defense capabilities is anticipated to drive growth in this sector [28] Group 5: Steel Industry - The steel industry is under scrutiny for overcapacity risks, with the China Iron and Steel Association emphasizing the need for strict control over production increases [19] - Stocks like Liugang Co. and Xining Special Steel have shown positive performance, reflecting market confidence despite regulatory pressures [20]

Market Performance - A-shares steadily advanced this week, with the ChiNext Index reaching a new high for the year and the Shenzhen Component Index hitting a four-month high, approaching its highest point of the year [1] - Weekly trading volume increased to 7.73 trillion yuan, marking the largest weekly trading volume in three months [1] Fund Inflows - Leverage funds actively entered the market, with most industries under the Shenwan first-level industry classification seeing net buying, particularly the computer industry with over 4.4 billion yuan and the electronics industry with over 3 billion yuan [2] - The electronic, biopharmaceutical, and automotive sectors each received over 20 billion yuan in net inflows, while the non-bank financial sector saw a net outflow of over 8.3 billion yuan [2] Rare Earth Demand - The rare earth sector performed strongly, with the rare earth permanent magnet index reaching a three-and-a-half-year high [3] - Demand for rare earths is expected to grow rapidly due to advancements in humanoid robots and electric vehicles, with estimates suggesting a demand of at least 70,000 tons of neodymium-iron-boron by 2025 [3] Energy Metals - The energy metals sector, including lithium and cobalt, reached a two-year high, with lithium carbonate futures breaking 70,000 yuan/ton, marking a 20% increase from recent lows [4] - Short-term lithium salt supply may decline due to reduced exports from Chile and domestic production halts, leading to a potential price stabilization [4] Biopharmaceutical Sector - The biopharmaceutical sector saw significant gains, with the innovative drug index hitting record highs multiple times this week [6] - Notable stocks in the sector, such as Lianhuan Pharmaceutical and Aosaikang, experienced consecutive trading halts, with some stocks showing year-to-date gains exceeding 200% [6][7] Earnings Forecasts - Several pharmaceutical companies have recently forecasted substantial profit increases for the first half of 2025, with estimates suggesting net profit growth exceeding 19 times for some firms [7]

Group 1 - The avian influenza concept sector declined by 0.90%, ranking among the top declines in concept sectors, with leading declines from companies such as Zhijiang Biology, Biological Shares, and Zhongmu Shares [1][2] - Among the 10 stocks that increased in price, Weilan Biology, Lianhuan Pharmaceutical, and Wens Foodstuff were the top gainers, with increases of 1.38%, 0.66%, and 0.53% respectively [1][2] - The avian influenza concept sector experienced a net outflow of 383 million yuan from main funds, with 17 stocks seeing net outflows, and 8 stocks with outflows exceeding 10 million yuan [2][3] Group 2 - The stock with the highest net outflow was Biological Shares, with a net outflow of 128 million yuan, followed by Zhongsheng Pharmaceutical, Taiji Group, and Zhijiang Biology with net outflows of 93.42 million yuan, 35.18 million yuan, and 33.51 million yuan respectively [2][3] - The stocks with the highest net inflows included Wens Foodstuff, Weilan Biology, and Oriental Biology, with net inflows of 16.02 million yuan, 13.06 million yuan, and 7.22 million yuan respectively [2][3] - The avian influenza concept sector's outflow list included Biological Shares, Zhongsheng Pharmaceutical, Taiji Group, and Zhijiang Biology, with respective declines of 5.56%, 0.45%, 0.27%, and 7.07% [2][3]

江苏联环药业股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的关于瑞卢戈利片的《药物临床 试验批准通知书》，现已正式取得瑞卢戈利片（以下简称"本品"）开展前列腺 癌临床试验的批准，并将于近期就本品开展"评价瑞卢戈利片治疗雄激素敏感 性进展期前列腺癌的有效性和安全性的Ⅲ期多中心临床试验"。现将相关情况公 告如下： 证券代码：600513 证券简称：联环药业 公告编号：2025—047 江苏联环药业股份有限公司 关于公司获得药物临床试验批准通知书的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、药品基本情况 药品名称：瑞卢戈利片 剂型：片剂 的 2 类改良新药 LH-2103 胶囊（详情请见公告：2025-013）。 截至本公告披露日，公司该项目累计已投入研发费用约为人民币 789.28 万 元（未经审计）。 申请事项：临床试验 受理号：CYHL2500092 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 05 月 13 日受理的瑞卢戈利片临床试 ...

Core Viewpoint - Company has received approval from the National Medical Products Administration for clinical trials of Relugolix tablets, aimed at treating prostate cancer [1] Group 1: Company Developments - Company announced the approval of clinical trials for Relugolix tablets, a GnRH receptor antagonist, primarily used for prostate cancer and endometriosis treatment [1] - Current prostate treatment portfolio includes the marketed drug Apalutamide tablets and the clinical trial stage LH-2103 capsules [1] - Approval for clinical trials does not immediately impact the company's revenue or operational performance significantly [1] Group 2: Regulatory Aspects - The approval from the National Medical Products Administration allows the company to conduct clinical trials, which must be followed by further review and approval before the drug can be marketed [1]

Market Overview - As of July 17, the Shanghai Composite Index closed at 3516.83 points, up 13.05 points, with a gain of 0.37% [1] - The Shenzhen Component Index closed at 10873.62 points, up 152.81 points, with a gain of 1.43% [1] - The ChiNext Index closed at 2269.33 points, up 39.13 points, with a gain of 1.75% [1] Stock Performance - A total of 83 A-shares had a turnover rate exceeding 20% on this day, with Xinning Electric achieving a turnover rate of over 50% [1] - The top stocks by turnover rate included: - Xinning Electric (301388) with a closing price of 38.30 yuan and a turnover rate of 52.50%, up 0.31% [1] - Dayilong (002209) with a turnover rate of 49.98%, closing at 17.09 yuan, down 7.82% [1] - Beifang Changlong (301357) with a turnover rate of 48.34%, closing at 85.47 yuan, up 5.88% [1] - Mankun Technology (301132) with a turnover rate of 45.59%, closing at 39.88 yuan, up 20.01% [1] Notable Stocks - Other notable stocks with high turnover rates included: - Tongguan Copper Foil (301217) with a turnover rate of 40.44%, closing at 20.86 yuan, up 13.37% [1] - Yida Technology (301176) with a turnover rate of 36.95%, closing at 35.16 yuan, up 6.19% [1] - Nanjing Julong (300644) with a turnover rate of 29.86%, closing at 33.59 yuan, up 20.01% [1] Additional Stock Insights - Stocks with significant price movements included: - Huanbo Technology (002229) with a turnover rate of 34.18%, closing at 20.56 yuan, up 10.01% [1] - ST Lifan (300280) with a turnover rate of 24.36%, closing at 3.17 yuan, down 7.85% [2] - Shanghai Steel Union (300226) with a turnover rate of 22.51%, closing at 30.37 yuan, up 2.74% [3]

Group 1 - The stock of Lianhuan Pharmaceutical (600513) increased by 2.02% with a turnover rate of 27.60% and a trading volume of 1.35 billion yuan, showing a fluctuation of 9.79% [2] - The stock was listed on the Shanghai Stock Exchange due to its high turnover rate, with a net selling amount of 25.91 million yuan from brokerage seats [2] - The top five brokerage seats accounted for a total transaction of 235 million yuan, with a buying amount of 105 million yuan and a selling amount of 131 million yuan, resulting in a net selling of 25.91 million yuan [2] Group 2 - The main buying brokerage was Guotai Junan Securities Headquarters, with a buying amount of 42.78 million yuan, while the largest selling brokerage was Guotai Junan Securities Shanghai Songjiang District Zhongshan Road Securities Office, with a selling amount of 51.84 million yuan [2][3] - The stock experienced a net outflow of 91.91 million yuan in main funds, with a significant outflow of 15.72 million yuan from large orders and 76.19 million yuan from major funds, while the net inflow over the past five days was 48.01 million yuan [2] - The company reported a first-quarter revenue of 628 million yuan, representing a year-on-year increase of 18.78%, but the net profit was 23.06 million yuan, a year-on-year decrease of 29.15% [2] Group 3 - On July 15, the company released a half-year performance forecast, expecting a net loss between 45 million yuan and 38 million yuan [3] - The trading data on July 17 showed continued activity with significant buying and selling amounts from various brokerages, indicating ongoing market interest [3][4]